You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
疫苗股普遍反彈 開拓(09939.HK)急漲18% 惟康希諾及三葉草反覆續跌近2%
美國兩大藥廠默克(MRK.US)及輝瑞(PFE.US)先後發佈研發新冠口服藥臨牀試驗療效顯着,市場憂慮新冠疫苗需求下降,本港上市疫苗股繼昨天全面捱沽後,今天普遍反彈,尤其是開拓藥業-B(09939.HK)繼昨天跌至33元逾半年低位獲承接收窄大部分跌幅後,今天股價扭兩連跌重越20天及牛熊線(41.5元41.3元),最高見47.8元,半日收46.4元,急漲18%,半日成交407萬股。 藍籌藥明生物(02269.HK)扭四連跌,股價由逾七個月低位反彈,最高見101元,半日收100.9元,回升8.4%,爲最強藍籌。 今年7月中旬才以每股22.25元上市的騰盛博藥-B(02137.HK)繼昨日急跌至17.3元上市新低喘定後,今天高見19.48元,半日收18.9元,回升5%。復星醫藥(02196.HK)扭三連跌,股價由逾一個月低位重越10天線(36.35元),最高見36.9元,半日收36.45元,回升2.5%。 然而,康希諾生物-B(06185.HK)四連跌,股價繼昨天急跌7%低見153元創近一年低喘定,今早曾反彈至163.9元無以爲繼,掉頭低見154元,半日收156.2,續跌1.9%。 以每股13.38元上市掛牌第三天的三葉草生物-B(02197.HK)繼昨天急跌29%低見8.8元喘定後,今早股價仍反覆受壓,高低見9.75元/8.94元,現報9.04元,續跌1.7%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account